{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"<div>COLOPREDICT PLUS 2.0 Register</div><div>Retro- und prospektive Erfassung der Rolle von MSI und KRAS f&#252;r die Prognose beim Kolonkarzinom im Stadium I + II + III</div><div><br /></div><div>DRKS00004305 (keine weiteren Registriernummern)</div>","eudractNumber":null,"id":9356,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-08-31T10:12:47+02:00","shortTitle":"ColoPredict Plus 2.0 Register","therapeutical":false,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Ein Register f&#252;r Befunde und Videos von Endoskopien in der Gastroenterologie","eudractNumber":null,"id":11473,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT06920680","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-07-25T09:29:41+02:00","shortTitle":"ColoReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Postoperative Betreuung von Patienten mit tiefem anterioren Resektionssyndrom (LARS) nach operativer Behandlung des Rektumkarzinoms.<div><br /></div><div>DRKS00033615</div>","eudractNumber":null,"id":10726,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-07-01T11:36:50+02:00","shortTitle":"Coloplast/LARS Studie","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Direkte Detektion von Immunmolek&#252;len im Malignen Melanom","eudractNumber":null,"id":5163,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2019-02-11T09:38:26+01:00","shortTitle":"CryptaMel","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)</div>","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T08:46:54+02:00","shortTitle":"D702FC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients With Relapsed or Refractory Multiple Myeloma","eudractNumber":"2023-508590-89-00","id":9058,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06106945","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-01-16T09:53:56+01:00","shortTitle":"D7230C00001","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)","eudractNumber":"2023-505789-27-00","id":9783,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06526793","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-04-23T14:08:33+02:00","shortTitle":"D7404C00001 Soundtrack B","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia","eudractNumber":"2023-505840-20","id":8894,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT06137118","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2024-10-04T15:01:33+02:00","shortTitle":"D7405C00001","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the \nSafety and Efficacy of AZD0486 Monotherapy or in Combination with \nOther Anticancer Agents in Participants with Mature B-Cell Malignancies","eudractNumber":"2024-515034-33","id":10004,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-05-21T11:39:54+02:00","shortTitle":"D7407C00001 Soundtrack E","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Modular Phase I/II Open-label Dose Escalation and Dose \nExpansion Study to Evaluate the Safety, Pharmacokinetics, \nPharmacodynamics, and Efficacy of AZD5492, a T cell-engaging \nAntibody Targeting CD20 in Subjects with Relapsed or Refractory \nB-Cell Malignancies (TITANium)&#160;","eudractNumber":"2024-511099-34-00","id":10005,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT06542250","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-01-14T15:09:54+01:00","shortTitle":"D9960C00001 TITANium","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]}]}